Cells for Cells (“C4C”) was founded in 2010 as a spin-off of Universidad de los Andes (Chile) when it opened the field of regenerative medicine to patients in South America. Since then, the company has conducted eight clinical trials (>800 treated patients), published more than 120 scientific articles, and applied for 17 patent families. These results situate C4C as one of the world’s most productive global cell therapy companies. By securing nearly US$ 20 million through non-diluting governmental grants, C4C has de-risked several groundbreaking technologies at a fraction of the cost required in other countries with well-established scientific culture and support. This cost-efficient management led the company to achieve rapid clinical validation of its proprietary exosome technology platform, C4C’s most promising asset. The milestone above meant C4C’s exosome therapy for symptomatic osteoarthritis was the first of its kind in the race to the bedside, positioning C4C at the forefront of the industry.
Our Story
Trailblazing regenerative medicine in South America
